跳到主要內容

臺灣博碩士論文加值系統

(44.200.168.16) 您好!臺灣時間:2023/03/21 16:26
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:莊佩潔
研究生(外文):Pei-Chieh Chuang
論文名稱:生物活性因子應用於眼表疾病治療之新商業模式探討
論文名稱(外文):A Review of Market Application and Business Model of Ocular Surface Disease Treatment Using Bioactive Factors.
指導教授:楊台鴻
指導教授(外文):Tai-Horng Yang
口試委員:王一中王宗仁溫育芳
口試委員(外文):I-Jong WangTsung-Jen WangYue-Fang Wen
口試日期:2020-07-30
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:生物科技管理碩士在職學位學程
學門:商業及管理學門
學類:其他商業及管理學類
論文種類:學術論文
論文出版年:2020
畢業學年度:108
語文別:中文
論文頁數:54
中文關鍵詞:眼科乾眼症生物活性因子富含血小板血漿商業模式
外文關鍵詞:OphthalmologyDry Eye DiseaseBioactive FactorsPRPBusiness Model
DOI:10.6342/NTU202002791
相關次數:
  • 被引用被引用:0
  • 點閱點閱:63
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
乾眼症儼然已成為現代文明病,近年來隨著生活型態改變、生活仰賴3C產品、加上雷射手術的後遺症,罹患乾眼症的年齡層逐步降低,再加上人口高齡化的趨勢,罹患乾眼症患者人數日益增加。
乾眼症治療市場持續增長,然而至今乾眼症尚無有效治療方式,本研究希望透過文獻分析與商業模式探討,以探究已在骨科、運動醫學廣泛使用的再生醫學領 “自體生物活性因子” 用於乾眼症治療之可行性及導入自動化系統的商業模式。
Dry eye disease (DED) has become a public health issue recently. Since life style change, increasing and constant use of digital devices, increasing eye LASIK surgery, prevalence has increasing rapidly both in older adults and younger populations.
With the increasing market in Dry eye disease, it is important to establish effective treatments. This study intends to figure out the feasibility of using Bioactive Factors in Ocular surface disease treatment, and the business model to introducing an automatic autologous bioactive factors collection device into market.
口試委員會審定書 #
誌謝 i
中文摘要 ii
ABSTRACT ii
CONTENTS iii
表目錄 v
圖目錄 vi
附 錄 vii
第一章 緒論 1
1.1 研究動機 1
1.2 研究問題與目的 5
1.3 研究方法及限制 5
1.4 研究流程 6
第二章 文獻探討 7
2.1 商業模式圖 (Business Model Canvas) 7
2.2 價值主張圖 (Value Proposition) 8
2.2.1 顧客素描 (Customer Profile) 8
2.2.2 價值地圖 (Value Map) 9
2.3 產業五力分析 10
第三章 產業技術 12
3.1 自體生物活性因子(Autologous Bioactive molecules,ABM)簡介 12
3.2 乾眼症概述 13
3.3 自體生物活性因子於乾眼症的應用 20
第四章 乾眼症治療商業模式分析 29
4.1 台灣乾眼症治療市場現行商業模式 29
4.2 價值主張圖 33
4.2.1 乾眼症市場顧客素描 (Customer Profile) 33
4.2.2 價值地圖 (Value Map) 36
4.2.3 價值適配交叉分析 39
4.3 乾眼症治療創新商業模式 40
4.4 SWOT分析 42
4.5 五力分析 43
第五章 結論與研究建議 45
參考文獻 49
附錄一、乾眼症新商業模式訪談大綱 54
英文文獻
[1].Porter,M. E. "How competitive forces shape strategy", Harvard Business Review, March/April 1979.
[2].Osterwalder,A., et al. Value proposition design: How to create products and services customers want. John Wiley & Sons. 2014.
[3].Lanning, M. J., et al. A business is a value delivery system. McKinsey staff paper, 41. July, 1988.
[4].Robert M. Grant. Contemporary Strategy Analysis. 2002.
[5].Osterwalder,A., et al. Business Model Generation: A Handbook for Visionaries, Game Changers, and Challengers. Wiley.com. 2010
[6].C. K. Prahalad & G.Hamel. "The core competence of the Corporation" Harvard Business Review, Jun/July 1990
[7].Yu-Kai Kuo, I-Chan Lin.; et al Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits. J. Clin. Med. 2019, 8, 1227
[8].Lin, P.Y. et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology. 2003, 110, 1096-1101.
[9].J.D. Nelson, et al. TFOS DEWS II Introduction The Ocular Surface 15 (2017) 269-275
[10].Jennifer P. Craig, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface 15 (2017) 276-283
[11].Suvarna P. Phadatare, et al. A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments,and Future Challenges. Advances in Pharmaceutics.Volume 2015, Article ID 704946, 12 pages
[12].McDonald, et al. Economic and Humanistic Burden of Dry Eye Disease in Europe, NorthAmerica, and Asia: A Systematic Literature Review. THE OCULAR SURFACE .APRIL 2016, VOL. 14 NO. 2
[13].Edward S Jarka, et al. Review of Sjögren Syndrome: A Comparison of Two Topical Biologic Treatment Options. . J Ophthalmic Clin Res 2016, 3: 024.
[14].Yu J, et al. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011; 30, 379-387.
[15].Yao, Le, et al. Social-economic analysis of patients with Sjogren’s syndrome dry eye in East China: a cross-sectional study. BMC Ophthalmology. 2018;18:23
[16].Mizuno et al. Annual direct cost of dry eye in Japan. Clinical Ophthalmology. 2012:6 755-760.
[17].Messmer, EM, et al. The pathophysiology, diagnosis, and treatment of dry eye disease. Deutsches Arzteblatt international. 30 January 2015, 112 (5): 71–81; quiz 82. PMID 25686388
[18].Pflugfelder SC, et al.Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;113:541-552.
[19].Clegg JP, et al. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006;13:263-274.
[20].Enzenauer RW, et al. Relative costs of various preserved artificial tear solutions for the treatment of dry eye conditions. Eye Contact Lens. 2003;29:238-240.
[21].Reddy P, , et al.The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea. 2004;23:751-761.
[22].Reza Dana, et al. Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System. Am J Ophthalmology. 2019;202:47-54.
[23].Federico Bernabei, , et al. Blood-Based Treatments for Severe Dry Eye Disease:The Need of a Consensus. J. Clin. Med. 2019, 8, 1478
[24].William R, et al.Physiology of Blood Components in Wound Healing:an Appreciation of Cellular Co- Operativity in Platelet Rich Plasma Action. J Exerc Sports Orthop 2017 4(2):1-14.
[25].Thomas A. , et al. Macrophages in tissue repair, regeneration, and fibrosis. Immunity. 2016 Mar 15; 44(3): 450–462.
[26].Bona L, et al. Activated Platelets Induce an Anti-Inflammatory Response of Monocytes/Macrophages through Cross-Regulation of PGE2 and Cytokines. Mediators of Inflammation. Volume 2017, Article ID 1463216, 14 pages
[27].Meinrad Gawaz et al. Platelets in tissue repair: control of apoptosis and interactions with regenerative cells. BLOOD, 10 OCTOBER 2013 VOLUME 122, NUMBER 15.2550-2554
[28].Kazuo Tsubota et al. Treatment of dry eyes AS Application in Sjögren’s Syndrome. Br J Ophthalmol 1999;83:390–395
[29].Joanna von Hofsten, , et al. The use of AS for the treatment of ocular surface disease at a Swedish tertiary referral center. International Medical Case Reports Journal 2 Mar 2016
[30].Fox R, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984;27:459–61.
[31].Lubkowska, A. , et al. Growth factor content in PRP and their applicability in medicine. J. Biol. Regul. Homeost. Agents Apr-Jun 2012, 26, 3S–22S.
[32].Ian A. Jones et al. The Economics and Regulation of PRP in the Evolving Field of Orthopedic Biologics. Curr Rev Musculoskelet Med. 2018 Dec; 11(4): 558–565
[33].Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg. 2019 Jan 15;27(2):e50-e63
[34].Erminia Mariani et al, Platelet Concentrates in Musculoskeletal Medicine. Int. J. Mol. Sci. 2020, 21, 1328
[35].Alio J.L., et al. Treatment of ocular surface syndrome after LASIK with autologous platelet-rich plasma. J. Refract. Surg. 2007;23:617–619.
[36].Alio J.L., et al. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007;114:1286–1293.
[37].Alio J.L., et al. Autologous Platelet-Rich Plasma Eye Drops for the Treatment of Post-LASIK Chronic Ocular Surface Syndrome. J. Ophthalmology. 2017; 2017
[38]. Alio J.L., et al. A. Symptomatic dry eye treatment with autologous platelet-rich plasma. Ophthalmic Res. 2007;39:124–129.
[39].Stacie G. et al, Platelet-Rich Plasma: A Milieu of Bioactive Factors. Arthroscopy: The Journal of Arthroscopic and Related Surgery. Vol 28, No 3 March, 2012: pp 429-439
[40].Dines JS. Growth factor confusion. Arthroscopy 2010;26: 1144, author reply 1145-1146.
[41].Behrens A, et al. Dysfunctional tear syndrome. A Delphi approach to treatment recommendations. Cornea 2006;25:90-7
[42].Kazuo Tsubota MD, et al. New Perspectives on Dry Eye Definition and Diagnosis: A Consensus Report by the Asia Dry Eye Society. The Ocular Surface. Volume 15, Issue 1, January 2017, Pages 65-76
[43].Panda A., et al. Topical autologous platelet-rich plasma eyedrops for acute corneal chemical injury. Cornea. 2012;31:989–993.
[44].García-Conca V., et al. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol. 2019;97:e170–e178.
[45].Avila M.Y., et al. Randomised, prospective clinical trial of platelet-rich plasma injection in the management of severe dry eye. Br. J. Ophthalmol. 2019;103:648–653.
[46].Kim K.M., et al. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn. J. Ophthalmol. 2012;56:544–550. doi: 10.1007/s10384-012-0175-y
[47].Lee J.H., et al. Autologous platelet-rich plasma eye drops in the treatment of recurrent corneal erosions. Korean J. Ophthalmol. 2016;30:101–107.
[48].Wróbel-Dudzińska D., et al. Clinical efficacy of platelet-rich plasma in the treatment of neurotrophic corneal ulcer. J. Ophthalmol. 2018;2018:3538764.
[49].Andrea Piccin, et al. Platelet gel: a new therapeutic tool with great potential. Blood transfusion. July 2016;15(4):1-8

中文文獻
[50].朱文儀、陳建男(譯) Charles W.L. Hill,Melissa A. Schilling,Grareth R. Jones著,策略管理(Strategic Managemnet Theory 12TH Edition),2017


網路資料
[51].http://www.genetinfo.com/investment/featured/item/27897.html?start=4
[52].Coherent Market Insights. DRY EYE SYNDROME TREATMENT MARKET ANALYSIS
[53].https://www.stemcell.com/cell-separation/isolate-cells-from-blood
[54].https://zh.wikipedia.org/wiki/白血球
[55].https://www.histology.leeds.ac.uk/blood/blood_wbc.php
[56].康健知識庫網路文章https://kb.commonhealth.com.tw/library/98.html
[57].乾眼症眼科徐敏文主治醫師97年1月 http://www.kmuh.org.tw/www/kmcj/data/9701/9.htm
[58].台大醫院衛教天地 陳偉勵醫師https://www.bh.ntuh.gov.tw/hch/Upload/C347/眼科_乾眼症.pdf
[59].https://www.elite-o.com.tw/index.php/tw/prp-treatment/excellent-efficacy
[60].國內外乾眼病市場競爭格局 https://kknews.cc/health/343keyy.html
[61].Assessment of the Tear Film https://www.jnjvisioncare.ae/sites/default/files/public/ae/documents/assessment_of_the_tear_film.pdf
[62].中華民國醫師公會全國聯合會網站/ 醫療統計 https://www.tma.tw/stats/index_NYearInfo.asp?/2018.html
[63].衛部醫字第1061661725號公文會議紀錄
[64].醫療機構執行高濃度血小板血漿管理規範
連結至畢業學校之論文網頁點我開啟連結
註: 此連結為研究生畢業學校所提供,不一定有電子全文可供下載,若連結有誤,請點選上方之〝勘誤回報〞功能,我們會盡快修正,謝謝!
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top